Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 4/20 | 0.61 |
| ▸ | ABL1 | P00519 | 2/20 | 0.61 |
| ▸ | RAF1 | P04049 | 2/20 | 0.61 |
| ▸ | LYN | P07948 | 2/20 | 0.61 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 14/20 | 0.57 |
| ▸ | MAPK12 | P53778 | 11/20 | 0.56 |
| ▸ | HCK | P08631 | 9/20 | 0.56 |
| ▸ | TNF | P01375 | 3/20 | 0.56 |
| ▸ | GSK3B | P49841 | 2/20 | 0.55 |
| ▸ | SYK | P43405 | 1/20 | 0.55 |
| ▸ | GSK3A | P49840 | 1/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.55 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.55 |
| ▸ | CIT | O14578 | 1/20 | 0.54 |
| ▸ | MUSK | O15146 | 1/20 | 0.54 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.54 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.54 |
| ▸ | STK10 | O94804 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4087767 | 0.91 | MAPK14 (0.57) | SRCABL1RAF1LYNMAPK9 | |
| SCHEMBL4086637 | 0.85 | MAPK9 (0.56) | SRCABL1RAF1LYNMAPK9 | |
| SCHEMBL6178470 | 0.85 | ABL1 (0.62) | SRCABL1RAF1LYNMAPK9 | |
| SCHEMBL4088544 | 0.82 | MAPK14 (0.60) | SRCABL1RAF1LYNMAPK9 | |
| SCHEMBL5732031 | 0.80 | MAPK14 (0.49) | SRCABL1RAF1LYNMAPK9 | |
| SCHEMBL4091834 | 0.80 | MAPK14 (0.62) | SRCABL1RAF1LYNMAPK9 | |
| SCHEMBL4092182 | 0.79 | MAPK14 (0.56) | SRCABL1RAF1LYNMAPK9 | |
| SCHEMBL19731981 | 0.79 | MAPK14 (0.81) | SRCMAPK14MAPK12HCKGSK3B | |
| SCHEMBL4092132 | 0.79 | MAPK14 (0.56) | SRCABL1RAF1LYNMAPK9 | |
| SCHEMBL4086255 | 0.78 | SRC (0.61) | SRCABL1RAF1LYNMAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6835832-B2 | Catalytic hydrogenation | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-12-28 | — | — | US | disclosed |
| US-6774233-B2 | AUTOIMMUNE DISEASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-08-10 | — | — | US | disclosed |
| US-6753426-B2 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-06-22 | — | — | US | disclosed |
| US-20030166930-A1 | Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | US | disclosed |
| US-20030166931-A1 | Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | US | disclosed |
| US-6583282-B1 | Formation of a urea by reacting an aromatic carbamate with a aromatic amine | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-06-24 | — | — | US | disclosed |
| US-20030109703-A1 | Polymorph and process for preparing same | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-06-12 | — | — | US | disclosed |
| EP-1200411-A2 | NOVEL PROCESS FOR SYNTHESIS OF HETEROARYL-SUBSTITUTED UREA COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001004115-A2 | NOVEL PROCESS FOR SYNTHESIS OF HETEROARYL-SUBSTITUTED UREA COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166931-A1 | Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents | URB2, UGT1A1, PURB | SRC 2318/4885ABL1 2055/4885RAF1 1359/4885 |
| US-20030109703-A1 | Polymorph and process for preparing same | UGT1A1, CYP1A1, CYP1B1 | SRC 1962/4885ABL1 1839/4885RAF1 1377/4885 |
| US-20030166930-A1 | Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents | URB2, UGT1A1, PURB | SRC 2318/4885ABL1 2055/4885RAF1 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.